Biogen Idec, Stromedix deal

Biogen Idec will acquire Stromedix for $75 million up front, and up to $487.5 million in milestones. Stromedix is developing STX-100, a humanized mAb against integrin alpha(V)beta(6), to treat fibrotic disease. The product is in a Phase II trial to treat idiopathic pulmonary fibrosis (IPF). Stromedix also has identified a series of clinical biomarkers that reflect the biological activity of STX-100 and has a preclinical compound in development to treat injury due to inflammation. ...